STAND STRONG AGAINST INFLUENZA

A trusted influenza vaccine for people 6 months and older.1

Order AFLURIA®  QUADRIVALENT

These days, who has time for influenza?
AFLURIA QUADRIVALENT can help.

AFLURIA QUADRIVALENT is an influenza vaccine for people 6 months and older produced through the traditional egg-based manufacturing process.

Stand strong against influenza with
AFLURIA QUADRIVALENT

35.6 million

illnesses in the US estimated every year2

up to 710,000

hospitalizations estimated annually in the US since 20102

projected 87.1 billion

economic burden in USD for people in the US3

Review AFLURIA QUADRIVALENT information here

AFLURIA QUADRIVALENT is an influenza vaccine for people 6 months and older produced through the traditional egg-based manufacturing process.

  • For intramuscular injection only
  • AFLURIA QUADRIVALENT is supplied in 3 product presentations: as a package of ten 0.5-mL prefilled needleless syringes or as a 5-mL multidose vial
  • Administer AFLURIA QUADRIVALENT as a 0.25-mL dose for patients 6-35 months of age, and as a 0.5-ml dose for patients 36 months of age and older
  • Both the multidose vial and prefilled syringe presentations are not made with natural rubber latex
  • The prefilled syringe presentation is preservative free

Store AFLURIA QUADRIVALENT refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. Discard if the vaccine has been frozen. Do not use after expiration date.

Order AFLURIA QUADRIVALENT today

Important Safety Information

AFLURIA QUADRIVALENT

INDICATION

AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. AFLURIA QUADRIVALENT is approved for use in persons 6 months of age and older.

CONTRAINDICATIONS

  • Severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

  • If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
  • Immunocompromised persons may have a diminished immune response to AFLURIA QUADRIVALENT.

ADVERSE REACTIONS

  • In adults 18 through 64 years, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain(≥40%). The most common systemic adverse events were myalgia and headache(≥20%).
  • In adults 65 years of age and older, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain(≥20%). The most common systemic adverse events was myalgia(≥10%).
  • In children 5 through 8 years, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain(≥50%), redness and swelling(≥10%). The most common systemic adverse events was headache(≥10%).
  • In children 9 through 17 years, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain(≥50%), redness and swelling(≥10%). The most common systemic adverse events were myalgia, headache, and malaise and fatigue(≥10%).
  • In children 6 months through 35 months of age, the most commonly reported injection-site reactions were pain and redness(≥20%). The most common systemic adverse events were irritability(≥30%), diarrhea and loss of appetite(≥20%).
  • In children 36 through 59 months of age, the most commonly reported injection site reactions were pain(≥30%) and redness(≥20%). The most commonly reported systemic adverse events were malaise and fatigue, and diarrhea(≥10%).

  • The safety experience with AFLURIA (trivalent formulation) is relevant to AFLURIA QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions:


  • In adults 18 through 16 64 years of age, the most commonly reported injection-site adverse reaction with AFLURIA (trivalent formulation) when administered by the PharmaJet Stratis Needle-Free Injection System were tenderness(≥80%), swelling, pain, redness(≥60%), itching(≥20%) and bruising (≥10%). The most common systemic adverse events were myalgia, malaise(≥30%), and headache(≥20%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc, at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.


Please see full Prescribing Information for AFLURIA QUADRIVALENT.


AFLURIA is a registered trademark of Seqirus UK Limited or its affiliates.


PharmaJet® and STRATIS® are registered trademarks of PharmaJet.

References

1. AFLURIA QUADRIVALENT [package insert]. Summit, NJ: Seqirus USA Inc; 2018. 2. Centers for Disease Control. Disease Burden of Influenza. 2017-2018 https://www.cdc.gov/flu/about/disease/burden.html.Accessed 2017 3.Noelle-Angelique M. Molinari, Ismael R. Ortega-Sanchez, Mark L. Messonnier, William W. Thompson, Pascale M. Wortley, Eric Weintraub, Carolyn B. Bridges, “The annual impact of seasonal influenza in the US: Measuring disease burden and costs,” National Center for Biotechnology Information, June 28 2007, https://www.ncbi.nlm.nih.gov/pubmed/17544181.

LEARN.
ORDER.
MANAGE.

By creating an account with us, you can see specific product
pricing, make a purchase, and manage your shipments easily.